PUBLIC COMPANY
save$VERAVera Therapeutics, Inc.
$VERA30.29-4.08%Brisbane, CA, USupdated 3h ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2Monthly Dosing of Atacicept in IgAN
- phase2Atacicept in Multiple Glomerular Diseases
- phase3Atacicept in Subjects With IgA Nephropathy
- phase3Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
- phase2A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
- phase2A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 14, 26SELLFordyce Marshall· PRESIDENT AND CEO−$617K↗
- Apr 14, 26SELLFordyce Marshall· PRESIDENT AND CEO−$353K↗
- Apr 14, 26SELLFordyce Marshall· PRESIDENT AND CEO−$41K↗
- Feb 23, 26SELLFordyce Marshall· PRESIDENT AND CEO−$711K↗
- Feb 23, 26SELLGrant Sean· CHIEF FINANCIAL OFFICER−$208K↗
- Feb 23, 26SELLYoung Joseph R· SVP, FINANCE, CHIEF ACCT OFFCR−$131K↗
- Feb 23, 26SELLJOHNSON DAVID LEE· Chief Operating Officer−$108K↗
- Feb 23, 26SELLTurner William D.· Chief Regulatory Officer−$92K↗
- Feb 23, 26SELLBrenner Robert· Chief Medical Officer−$90K↗
- Feb 23, 26SELLSkelton Laurence Matthew· Chief Commercial Officer−$66K↗
routine RSU / option mechanics (5)
- Mar 23, 26grantWright-Mitchell Jane · Chief Legal Officer56,850 sh
- Mar 23, 26grantWright-Mitchell Jane · Chief Legal Officer42,403 sh
- Mar 13, 26option exerciseYoung Joseph R · SVP, FINANCE, CHIEF ACCT OFFCR10,000 sh
- Mar 13, 26option exerciseYoung Joseph R · SVP, FINANCE, CHIEF ACCT OFFCR10,000 sh
- Mar 5, 26grantHite Christopher · 24,937 sh
🐶 Hiring Signal
News
- Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drugThough it's no longer unusual for a startup to emerge with an investigational drug from China, an immunology biotech is adding that asset to two disease-controlling drugs it already discovered in-h…endpoints · 3h ago
- Boulevard starts up with $65M to pursue targeted autoimmune drugsCo-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.biopharma_dive · 3h ago
- Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugsBoulevard Bio has strolled out of stealth with $65 million in funding from Deerfield Management and three autoimmune disease candidates.fiercebiotech · 1d ago
- Silence causes uproar in rare blood cancer space as data sets high bar for competitorsThe mid-stage win of Silence Therapeutics’ siRNA drug in polycythemia vera validates the therapeutic approach of similar assets in development—but also sets a high standard for therapies from Taked…biospace · 1d ago
- Silence spells out Phase 2 success for gene-silencing drug in rare blood cancerSilence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial. Silence said Monday that its drug ...endpoints · 2d ago
- STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancerA rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.stat · 2d ago
- Silence brings the noise to Takeda with phase 2 blood cancer winA phase 2 trial of Silence Therapeutics’ divesiran has hit its primary endpoint, emboldening the biotech to gear up for late-phase development of a potential challenger to Takeda and Protagonist Th…fiercebiotech · 2d ago
- Why Big Pharma is chasing the industry’s most-powerful supercomputerBristol Myers Squibb is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.biopharma_dive · 5d ago
- Takeda’s narcolepsy nod opens orexin doorsOrzeyful is the first orexin agonist cleared by the FDA, and is the first narcolepsy therapy that addresses the full host of disease symptoms. It is "likely to reshape the treatment paradigm” for t…biospace · 6d ago
- Vertex unfazed by competitive IgAN space as FDA verdict loomsPositive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said…biospace · 8d ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that